TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02006836

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pomelo
Description: The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pomelo
Description: The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pomelo
Description: The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Glucose
Description: We dissolved 50 g of glucose in 200 ml water.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Glucose
Description: We dissolved 50 g of glucose in 200 ml water.

Intervention type: OTHER
Group type: OTHER
Intervention: Blank
Description: For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).

Intervention type: DRUG
Group type: OTHER
Intervention: met or diet
Description: In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
Study: NCT04343833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate dental implants
Description: At the time of operation, the tooth was atraumatically extracted, and the implant was immediately placed following the surgical protocol recommended by the manufacturer. A temporary prosthesis was made without occlusal contact.
Study: NCT00941382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg per day for 180 days
Study: NCT00417482

Intervention type: DRUG
Group type: OTHER
Intervention: risperidone
Description: Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial

Intervention type: DRUG
Group type: OTHER
Intervention: risperidone
Description: Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial

Intervention type: DRUG
Group type: OTHER
Intervention: risperidone
Description: Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
Study: NCT03403270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENCOURAGE App
Description: Users will have an opportunity to engage with the app as described for the duration of the study period.
Study: NCT02793193

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo for antibiotic
Description: The placebo supplementation is identical-looking to the antibiotic Xifaxan ®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Antibiotic Xifaxan ® will be 200mg per tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo for probiotic
Description: The placebo identical-looking to the probiotic B.longum 1714
Study: NCT04330196

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: Participant ingests 75g of glucose

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Ingestion of placebo
Description: Participant ingests 700mg of aspartame
Study: NCT01859585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: Parecoxib 40 mg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 30 mg intravenous
Study: NCT04054154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography
Description: Undergo shear wave elastography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Interstitial Fluid Pressure Measurement
Description: Undergo tumor pressure measurement
Study: NCT02236481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF alpha inhibitors
Study: NCT00666796

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ethanol
Description: Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ethanol
Description: Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
Study: NCT01374711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IFN-Y
Description: IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E.coli endotoxin
Description: 2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E.coli endotoxin
Description: 2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E.coli endotoxin
Description: 2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
Study: NCT03911219

Intervention type: OTHER
Intervention: eHealth system support for symptom management via CANKADO
Description: Regular use of eHealth support system CANKADO by the patient: symptom self-reporting triggering alerts to the patient; in addition to standard of care symptom management.
Study: NCT04343833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate dental implants
Description: At the time of operation, the tooth was atraumatically extracted, and the implant was immediately placed following the surgical protocol recommended by the manufacturer. A temporary prosthesis was made without occlusal contact.
Study: NCT04178863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CATS Tonometer
Description: latanoprost vs. timolol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CATS Tonometer
Description: latanoprost vs. timolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: latanoprost IOP reduction
Study: NCT02262221

Intervention type: OTHER
Group type: OTHER
Intervention: Scheduled radiologic evaluations
Description: Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
Study: NCT00485342

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Peg-interferon alpha 2a and ribavin
Description: Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin with adaptation dose
Description: Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks
Study: NCT04882605

Intervention type: GENETIC
Intervention: MHC typing
Description: Allelic genotyping resolution of MHC genes (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, -DPB1 and -DRB3/4/5) using Illumina technology.

Intervention type: GENETIC
Intervention: MHC typing
Description: Allelic genotyping resolution of MHC genes (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, -DPB1 and -DRB3/4/5) using Illumina technology.

Intervention type: GENETIC
Intervention: KIR typing
Description: Allelic genotyping resolution of all 13 KIR genes (KIR2DL1, KIR2DL2/2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS3/2DS5, KIR2DS4, KIR3DL1/3DS1, KIR3DL2, KIR3DL3), 2 KIR pseudogenes (KIR2DP1 and -3DP1) using Illumina technology.
Study: NCT00559936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Avastin 1%
Description: Avastin (bevacizumab) 1%
Study: NCT01827280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
Study: NCT00679055

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-0736
Description: MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo (unspecified)
Description: Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
Study: NCT04882605

Intervention type: GENETIC
Intervention: KIR typing
Description: Allelic genotyping resolution of all 13 KIR genes (KIR2DL1, KIR2DL2/2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS3/2DS5, KIR2DS4, KIR3DL1/3DS1, KIR3DL2, KIR3DL3), 2 KIR pseudogenes (KIR2DP1 and -3DP1) using Illumina technology.

Intervention type: GENETIC
Intervention: Assessment of KIR-based prediction scores
Description: Compiling donor/recipient MHC and KIR typings into 28 major KIR-based prediction scores
Study: NCT03580148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone
Description: Patients randomized to receive this study intervention will undergo one ultrasound guided 80mg Depo Medrol GHJ injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspirate
Description: Patients randomized to receive this study intervention will have, under sterile conditions and after injection of local anesthetic, 10 mls of bone marrow aspirate taken from the posterior superior iliac spine and injected under ultrasound guidance to the glenohumeral joint
Study: NCT04882605

Intervention type: GENETIC
Intervention: Assessment of KIR-based prediction scores
Description: Compiling donor/recipient MHC and KIR typings into 28 major KIR-based prediction scores
Study: NCT02012777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
Study: NCT03622749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Non-Invasive neuromodulation
Study: NCT01367119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methohexital
Description: Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.
Study: NCT04120493

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intra-striatal rAAV5-miHTT
Description: One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intra-striatal rAAV5-miHTT
Description: One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intra-striatal rAAV5-miHTT
Description: One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Imitation (sham) surgery
Description: Simulated surgical procedure with skin incisions only; no intrastriatal injections and no burr holes through the skull
Study: NCT04512625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Desensitizers
Description: The main aims and objectives of the present study were to evaluate and compare the effectiveness of three commercially available desensitizing agents: Gluma (Hareus Kulzer), Sheildforce Plus (Tokuyama), and Telio CS (Ivoclar Vivadent) desensitizer in reducing the pre- and post-cementation sensitivity for full coverage restorations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Desensitizers
Description: The main aims and objectives of the present study were to evaluate and compare the effectiveness of three commercially available desensitizing agents: Gluma (Hareus Kulzer), Sheildforce Plus (Tokuyama), and Telio CS (Ivoclar Vivadent) desensitizer in reducing the pre- and post-cementation sensitivity for full coverage restorations.
Study: NCT03474315

Intervention type: DIAGNOSTIC_TEST
Intervention: Multivariate assessment
Description: Patient's status assessment according to clinical evaluation and data acquired from the implanted device.
Study: NCT04455243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: 150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered in the same schedule and volume as NAC
Study: NCT04095156

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro assays.
Description: Biochemical and flow-cytometry analysis of specimen collected.
Study: NCT04512625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Desensitizers
Description: The main aims and objectives of the present study were to evaluate and compare the effectiveness of three commercially available desensitizing agents: Gluma (Hareus Kulzer), Sheildforce Plus (Tokuyama), and Telio CS (Ivoclar Vivadent) desensitizer in reducing the pre- and post-cementation sensitivity for full coverage restorations.
Study: NCT00504556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban (DU-176b)
Description: 30mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban (DU-176b)
Description: 60mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban (DU-176b)
Description: 30mg tablet two times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban (DU-176b)
Description: 60mg tablet two times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: warfarin tablets
Study: NCT01578564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR-C13
Description: Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
Study: NCT02480985

Intervention type: OTHER
Group type: OTHER
Intervention: Pituitary function evaluation
Description: Pituitary function evaluation performed at hospital discharge, 6 and 12 months~* Thyroid-stimulating hormone, free T4 and T3~* Follicle stimulating hormone, luteinizing hormone, estradiol, bioavailable testosterone~* Adrenocorticotropic hormone stimulation test~* Glucagon test (growth hormone deficit)~Risk factors evaluation of pituitary dysfunction~* Demographic data~* Daily data (clinical exam, secondary brain injuries)~* Hormone levels on day 1, 3 and 7~* Biomarkers on day 1, 3 and 7~* Brain CT-Scan on day 1~* Pituitary MRI on day 7~Outcome measures at 6 and 12 months~* Neurological recovery (GOSe)~* Independent functioning (FIM)~* Quality of life (EQ-5D-5L)~* Life satisfaction (LISAT-11)~* Depression (PHQ-9)
Study: NCT03810365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral treatment for insomnia
Description: Brief Behavioral Treatment for Insomnia includes content on sleep restriction, stimulus control, and sleep hygiene content with 1 month for primary outcome followed by 3 month 12 month follow-up visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Eating Control
Description: Healthy eating control involves healthy eating content with 1 month for primary outcome followed by 3 month and 12 month follow-up visits.
Study: NCT04402814

Intervention type: DIAGNOSTIC_TEST
Intervention: Clungene rapid test cassette
Description: Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clungene rapid test cassette
Description: Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.
Study: NCT01103115

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium 600mg plus Vit D 400 IU
Description: Daily supplementation with 600mg Calcium plus 400IU Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium 600mg plus Vit D 800 IU
Description: Daily supplementation with 600mg Calcium plus 800IU Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets
Study: NCT00963885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Copegus
Description: 1000 or 1200mg po daily for 24 or 48 weeks
Study: NCT00963885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000 or 1200mg po daily for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000 or 1200mg po daily for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000 or 1200mg po daily for 24 or 48 weeks
Study: NCT03008408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study: NCT00963885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Copegus
Description: 1000 or 1200mg po daily for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000 or 1200mg po daily for 24 or 48 weeks
Study: NCT03674840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angle kappa based SBL-3 implantation
Description: SBL-3 implantation based on kappa angle guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 0 to 180 degree SBL-3 implantation
Description: SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
Study: NCT00963885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegasys
Description: 180micrograms sc weekly for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180micrograms sc weekly for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180micrograms sc weekly for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180micrograms sc weekly for 24 or 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegasys
Description: 180micrograms sc weekly for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180micrograms sc weekly for 24 or 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591 (Danoprevir)
Description: 300mg po q8h for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591 (Danoprevir)
Description: 600mg po q12h for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591 (Danoprevir)
Description: 900mg po q12h for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591 (Danoprevir)
Description: 300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks